Liver transplantation for acute liver failure due to efavirenz hepatotoxicity: The importance of routine monitoring

International Journal of STD and AIDS

Volumn 24, Issue 10, 2013, Pages 831-833

  Fink, Douglas L ^a   Bloch, Edward ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

AIDS; antiretroviral therapy; efavirenz; hepatotoxicity; HIV; liver transplantation; prevention; toxicity; treatment

Indexed keywords

EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

ACUTE LIVER FAILURE; ADULT; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER TOXICITY; LIVER TRANSPLANTATION; PRESCRIPTION; PRIORITY JOURNAL;

EID: 84887364033     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1177/0956462413483720     Document Type: Article

References (15)

1. Dieterich DT,Robinson PA,Love J, et al.Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.Clin Infect Dis. 20041;38:S80-S89.
2. Van den Berg-Wolf M,Hullsiek KH,Peng G, et al.Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.HIV Clin Trials. 2008;9:324-336.
3. Brück S,Witte S,Brust J, et al.Hepatotoxicity in patients prescribed efavirenz or nevirapine.Eur J Med Res. 2008;13:343-348.
4. Chu KM,Manzi M,Zuniga I, et al.Nevirapine- and efavirenz-associated hepatotoxicity under programmatic conditions in Kenya and Mozambique.Int J STD AIDS. 2012;23:403-407.
5. Yimer G,Amogne W,Habtewold A, et al.High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study.Pharmacogenomics J. 2012;12:499-506.
6. De la Calle C,Sánchez A,Cordero M, et al.Moderator effect of CYP2B6 genotype in HIV-1 patients with tuberculosis treated with rifampicin and efavirenz.J Int AIDS Soc. 2012;15:18364-18364.
7. Maimbo M,Kiyotani K,Mushiroda T, et al.CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.Eur J Clin Pharmacol. 2012;68:267-271.
8. Mugusi S,Ngaimisi E,Janabi M, et al.Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania.PLoS ONE. 2012;7:e40180-e40180.
9. Abrescia N,D'Abbraccio M,Figoni M, et al.Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment-naive female AIDS patient without hepatitis virus co-infection.J Antimicrob Chemother. 2002;50:763-765.
10. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep 2001;49:1153-1156.
11. Asboe D,Aitken C,Boffito M, et al.British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011.HIV Med. 2012;13:1-44.
12. Ko N-Y,Lai Y-Y,Liu H-Y, et al.Impact of the nurse-led case management program with retention in care on mortality among people with HIV-1 infection: a prospective cohort study.Int J Nurs Stud. 2012;49:656-663.
13. Gerver SM,Chadborn TR,Ibrahim F, et al.High rate of loss to clinical follow up among African HIV-infected patients attending a London clinic: a retrospective analysis of a clinical cohort.J Int AIDS Soc. 2010;13:29-29.
14. Rice BD,Delpech VC,Chadborn TR, et al.Loss to follow-up among adults attending human immunodeficiency virus services in England, Wales, and Northern Ireland.Sex Transm Dis. 2011;38:685-690.
15. Car J,Gurol-Urganci I,De Jongh T, et al.Mobile phone messaging reminders for attendance at healthcare appointments.Cochrane Database Syst Rev. 2012;7:CD007458-CD007458.